Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Management of Joint Replacement in Hemophilia a with Inhibitors during Emicizumab Prophylaxis

Elena Santagostino, Maria Elisa Mancuso, MD PhD, Cristina Novembrino, Massimo Anzoletti Boscolo, Marigrazia Clerici, Gianluigi Pasta, MD, Luigi Piero Solimeno, MD, Flora Peyvandi

Blood (2017) 130 (Supplement 1): 2360.

https://doi.org/10.1182/blood.V130.Suppl_1.2360.2360

Published: 2017

Journal Articles

Risk Factors for the Development of High-Titer Inhibitors in 260 Children with Severe Hemophilia a Born Between 1990 and 2009: The Remain Study

Blood (2016) 128 (22): 3774.

https://doi.org/10.1182/blood.V128.22.3774.3774

Published: 2016

Journal Articles

Characterization of Bleeding in Hemophilia Carriers and Comparison to Women with Type 1 Von Willebrand Disease, Type 3 Von Willebrand Disease Obligate Carriers and Controls

Natasha Amrita Satkunam, MBBS, MSc, Johnny Mahlangu, MD, Christoph Bidlingmaier, MD PD, Dr. MD, Maria Eva Mingot-Castellano, PhD, Meera B. Chitlur, MD, Patrick F. Fogarty, MD, Adam Cuker, MD MS, Maria Elisa Mancuso, MD PhD, Pal André Holme, PhD MD, Julie Grabell, BA, CCRP, Wilma Hopman, MA, Prasad Mathew, MD, Paula D. James, MD

Blood (2016) 128 (22): 875.

https://doi.org/10.1182/blood.V128.22.875.875

Published: 2016

Journal Articles

Source of Factor VIII Replacement (PLASMATIC OR RECOMBINANT) and Incidence of Inhibitory Alloantibodies in Previously Untreated Patients with Severe Hemophilia a: The Multicenter Randomized Sippet Study

Flora Peyvandi, MD PhD, Pier Mannuccio Mannucci, MD, Isabella Garagiola, PhD, Mohsen Elalfy, MD, Amal El-Beshlawy, MD, Madatha V. Ramanan, MD, Peyman Eshghi, MD, Suresh Hanagavadi, Ramabadran Varadarajan, MD, Mehran Karimi, MD, Mamta V. Manglani, MD, Cecil Ross, MD, Guy Young, MD, Tulika Seth, MD, Shashikant Apte, MD FRCPA, Dinesh M. Nayak, MD, Adriana C. Sandoval Gonzales, MD, Elena Santagostino, MD PhD, Maria Elisa Mancuso, MD PhD, Johnny N. Mahlangu, MD, Santiago Bonanad, PhD, Monica Cerqueira, MD, Nadia P. Ewing, MD, Christoph Male, MD MSC, Tarek Owaidah, MD FRCPA, Veronica Soto Arellano, MD, Nathan L. Kobrinsky, MD FRCP, Suvankar Majumdar, MD, Rosario Perez Garrido, MD, Anupam Sachdeva, Mindy Simpson, MD FAAP, Mathew Thomas, Ezio Zanon, MD, ALI Bulent Antmen, Kaan Kavakli, MD, Marilyn Manco-Johnson, MD, Monica Martinez, MD, Esperanza Marzouka, MS, PS, Maria Gabriella Mazzucconi, MD, Daniela Neme, MD, Angeles Palomo Bravo, MD, Rogelio Paredes Aguilera, MD, Alessandra Nunes Loureiro Prezotti, MD, Schmitt Klaus, MD, Brian M. Wicklund, MD MPH, Bulent Zulfikar, MD, Rosendaal R. Frits, MD PhD

Blood (2015) 126 (23): 5.

https://doi.org/10.1182/blood.V126.23.5.5

Published: 2015

Journal Articles

Patients with Mild Hemophilia a with Discrepant FVIII Assays: Thrombin Generation and Bleeding Phenotype

Maria Elisa Mancuso, MD PhD, Maria Rosaria Fasulo, MD, Antonino Cannavò, MD, Flora Peyvandi, MD PhD, Elena Santagostino, MD PhD

Blood (2014) 124 (21): 2844.

https://doi.org/10.1182/blood.V124.21.2844.2844

Published: 2014

Journal Articles

Is Hemophilia B Less Severe Than Hemophilia A? Results Of Global Coagulation Assays

Maria Rosaria Fasulo, MD, Maria Elisa Mancuso, MD, PhD, Veena Chantarangkul, Antonino Cannavò, MD, Marigrazia Clerici, Lidia Padovan, Erica Scalambrino, Flora Peyvandi, Armando Tripodi, MD, Elena Santagostino, MD, PhD

Blood (2013) 122 (21): 2352.

https://doi.org/10.1182/blood.V122.21.2352.2352

Published: 2013

Journal Articles

Thrombin Generation Assay During Orthopaedic Surgery In Hemophilia A With and Without Inhibitors: Results From In Vivo Studies

Maria Elisa Mancuso, MD, PhD, Armando Tripodi, MD, Veena Chantarangkul, Maria Rosaria Fasulo, MD, Marigrazia Clerici, Lidia Padovan, Erica Scalambrino, Flora Peyvandi, Elena Santagostino, MD, PhD

Blood (2013) 122 (21): 3591.

https://doi.org/10.1182/blood.V122.21.3591.3591

Published: 2013

Journal Articles

Rare Genetic Variants Of The Protein-Coding Area Of The Genome and The Risk Of Inhibitor Development: An Exome-Sequencing Study Of 28 Patients With Severe Hemophilia A

Luca A. Lotta, Marco Fornili, Federico Ambrogi, Maria Elisa Mancuso, MD, PhD, Elena Santagostino, MD, PhD, Isabella Garagiola, Sabrina Seregni, Donna M. Muzny, Ginger Metcalf, Richard A. Gibbs, Elia Biganzoli, Flora Peyvandi

Blood (2013) 122 (21): 571.

https://doi.org/10.1182/blood.V122.21.571.571

Published: 2013

Journal Articles

Immune Tolerance Induction (ITI) in Adults with Congenital Hemophilia: A Multicenter Experience

Rebecca Kruse-Jarres, MD/MPH, Maria Elisa Mancuso, MD, PhD, Eva Mingot Castellano, MD, Johnny Mahlangu, MD

Blood (2012) 120 (21): 1123.

https://doi.org/10.1182/blood.V120.21.1123.1123

Published: 2012

Journal Articles

Thrombin Generation Assay Is Not Able to Predict Hemostatic Efficacy of by-Passing Agents in Patients with Hemophilia and Inhibitors: Results From in Vivo Studies

Maria Elisa Mancuso, MD, PhD, Elena Santagostino, MD, PhD, Veena Chantarangkul, Marigrazia Clerici, Armando Tripodi, MD

Blood (2012) 120 (21): 41.

https://doi.org/10.1182/blood.V120.21.41.41

Published: 2012

Journal Articles

Source and Purity of Factor VIII Products As Risk Factors for Inhibitor Development In Previously Untreated Patients with Severe Hemophilia A

Maria Elisa Mancuso, MD, PhD, Pier Mannuccio Mannucci, MD, Angiola Rocino, MD, Isabella Garagiola, Annarita Tagliaferri, Elena Santagostino, MD, PhD

Blood (2011) 118 (21): 25.

https://doi.org/10.1182/blood.V118.21.25.25

Published: 2011

Journal Articles

Predictors of Sustained Virological Response After Antiviral Therapy for Chronic Hepatitis C In Patients with Hemophilia: The Role of the Interleukin-28B (IL28B) Polymorphism

Maria Elisa Mancuso, MD, PhD, Alessio Aghemo, MD, Elena Santagostino, MD, PhD, Maria Grazia Rumi, MD, Raffaele Bruno, MD, Massimo Colombo, MD, Pier Mannuccio Mannucci, MD

Blood (2011) 118 (21): 2276.

https://doi.org/10.1182/blood.V118.21.2276.2276

Published: 2011

Journal Articles

Thrombin Generation Test in Patients with Hemophilia and Inhibitors Treated with by-Passing Agents: Results From In Vivo Studies

Maria Elisa Mancuso, MD, PhD, Veena Chantarangkul, Armando Tripodi, Marigrazia Clerici, Licia Padovan, Laura Lemma, Elena Santagostino, MD, PhD

Blood (2011) 118 (21): 1216.

https://doi.org/10.1182/blood.V118.21.1216.1216

Published: 2011

Journal Articles

Transient Elastography (Fibroscan ® ) In Adult Patients with Inherited Bleeding Disorders and Chronic Hepatitis C.

Maria Elisa Mancuso, MD, PhD, Alessio Aghemo, MD, Paolo Bucciarelli, MD, Elena Santagostino, MD, PhD, Mariagrazia Rumi, MD, Massimo Colombo, MD, Pier M. Mannucci, MD

Blood (2010) 116 (21): 1413.

https://doi.org/10.1182/blood.V116.21.1413.1413

Published: 2010

Journal Articles

Type of Factor VIII Product as Inhibitor Risk Factor in Patients with Severe Hemophilia A and Null Mutations.

Maria Elisa Mancuso, MD, PhD, Pier Mannuccio Mannucci, MD, Angiola Rocino, MD, Isabella Garagiola, PhD, AnnaRita Tagliaferri, MD, Maurizio Margaglione, MD, Elena Santagostino, MD, PhD

Blood (2009) 114 (22): 3500.

https://doi.org/10.1182/blood.V114.22.3500.3500

Published: 2009

Journal Articles

Sequential Combined Bypassing Therapy (SCBT) Is Safe and Effective in the Treatment of Unresponsive Bleeding in Adults and Children with Haemophilia and Inhibitors.

Alessandro Gringeri, MD, MSc, Kathelijn Fischer, MD, PhD, MSc, Anastasia Karafoulidou, MD, Robert Klamroth, MD, Maria Fernanda Lopez, MD, Maria Elisa Mancuso, MD

Blood (2009) 114 (22): 1294.

https://doi.org/10.1182/blood.V114.22.1294.1294

Published: 2009

NARROW

Management of Joint Replacement in Hemophilia a with Inhibitors during Emicizumab Prophylaxis

Risk Factors for the Development of High-Titer Inhibitors in 260 Children with Severe Hemophilia a Born Between 1990 and 2009: The Remain Study

Characterization of Bleeding in Hemophilia Carriers and Comparison to Women with Type 1 Von Willebrand Disease, Type 3 Von Willebrand Disease Obligate Carriers and Controls

Source of Factor VIII Replacement (PLASMATIC OR RECOMBINANT) and Incidence of Inhibitory Alloantibodies in Previously Untreated Patients with Severe Hemophilia a: The Multicenter Randomized Sippet Study

Patients with Mild Hemophilia a with Discrepant FVIII Assays: Thrombin Generation and Bleeding Phenotype

Is Hemophilia B Less Severe Than Hemophilia A? Results Of Global Coagulation Assays

Thrombin Generation Assay During Orthopaedic Surgery In Hemophilia A With and Without Inhibitors: Results From In Vivo Studies

Rare Genetic Variants Of The Protein-Coding Area Of The Genome and The Risk Of Inhibitor Development: An Exome-Sequencing Study Of 28 Patients With Severe Hemophilia A

Immune Tolerance Induction (ITI) in Adults with Congenital Hemophilia: A Multicenter Experience

Thrombin Generation Assay Is Not Able to Predict Hemostatic Efficacy of by-Passing Agents in Patients with Hemophilia and Inhibitors: Results From in Vivo Studies

Source and Purity of Factor VIII Products As Risk Factors for Inhibitor Development In Previously Untreated Patients with Severe Hemophilia A

Predictors of Sustained Virological Response After Antiviral Therapy for Chronic Hepatitis C In Patients with Hemophilia: The Role of the Interleukin-28B (IL28B) Polymorphism

Thrombin Generation Test in Patients with Hemophilia and Inhibitors Treated with by-Passing Agents: Results From In Vivo Studies

Transient Elastography (Fibroscan ® ) In Adult Patients with Inherited Bleeding Disorders and Chronic Hepatitis C.

Type of Factor VIII Product as Inhibitor Risk Factor in Patients with Severe Hemophilia A and Null Mutations.

Sequential Combined Bypassing Therapy (SCBT) Is Safe and Effective in the Treatment of Unresponsive Bleeding in Adults and Children with Haemophilia and Inhibitors.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only